HomeGeneticsConditionJuvenile primary lateral sclerosis
Back to Condition
Juvenile primary lateral sclerosis
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Condition

Juvenile primary lateral sclerosis

Juvenile primary lateral sclerosis is a rare, progressive disorder caused by damage to motor neurons, leading to muscle weakness and spasticity.

Overview

Juvenile primary lateral sclerosis is a rare disorder characterized by progressive weakness and tightness (spasticity) of muscles in the arms, legs, and face. These features are caused by damage to motor neurons, which are specialized nerve cells in the brain and spinal cord that control muscle movement.

Symptoms

Symptoms typically begin in early childhood and progress slowly over many years. Early signs include:

  • Clumsiness
  • Muscle weakness and spasticity in the legs
  • Difficulty with balance

As the condition progresses, spasticity spreads to the arms and hands. Affected individuals may also develop:

  • Slurred speech
  • Drooling
  • Difficulty swallowing
  • Inability to walk

Causes

Most cases are caused by mutations in the ALS2 gene, which provides instructions for making a protein called alsin. Alsin is abundant in motor neurons, though its exact function is not fully understood. Mutations lead to unstable or non-functional alsin, which is believed to damage motor neurons, though the exact mechanism remains unclear.

Inheritance

When caused by mutations in the ALS2 gene, juvenile primary lateral sclerosis is inherited in an autosomal recessive pattern. This means both copies of the gene in each cell have mutations. Parents of an affected individual each carry one copy of the mutated gene but typically do not show signs or symptoms of the condition.

Frequently Asked Questions

Early clumsiness, frequent falls, and subtle leg weakness or stiffness in a child are classic initial clues. When these symptoms appear before age 25 and progress slowly, clinicians consider juvenile primary lateral sclerosis (JPLS) and will order a detailed neurologic exam and imaging to rule out other causes.
Diagnosis relies on a combination of clinical evaluation, electromyography (EMG) showing upper‑motor‑neuron signs without lower‑motor‑neuron loss, MRI of brain and spinal cord to exclude structural lesions, and genetic testing for ALS2 mutations. A neurologist may also perform nerve conduction studies and assess muscle tone and reflexes.
No cure exists, but symptom‑focused treatments help. Antispasticity drugs (baclofen, tizanidine), physical therapy to maintain range of motion, and occupational therapy for hand function are standard. Some centers use experimental agents targeting ALS2 pathways in clinical trials; discuss trial eligibility with a specialist.
JPLS due to ALS2 follows an autosomal‑recessive pattern. Each sibling has a 25 % chance of being affected, a 50 % chance of being a carrier, and a 25 % chance of being unaffected and not a carrier. Carrier testing of parents and at‑risk relatives is available through targeted ALS2 genetic analysis, and prenatal or pre‑implantation genetic diagnosis can be considered for future pregnancies.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA